Peter Demopulos Biography and Net Worth

Director of Omeros

Dr. Demopulos has served on our board of directors since January 1995. Dr. Demopulos is a practicing board-certified general and interventional cardiologist at Seattle Cardiology, part of the Swedish Heart & Vascular Institute. He has been a member of Seattle Cardiology since 2005, serving as its medical director from 2005 to 2010. Dr. Demopulos is also a clinical assistant professor of cardiology at the University of Washington School of Medicine, a position that he has held since 1989. He participates as an investigator in clinical trials evaluating interventional cardiology devices and drug therapies at Seattle Cardiovascular Research and Swedish Cardiovascular Research. He is a fellow of both the American College of Cardiology and the Society for Cardiovascular Angiography and Interventions. Dr. Demopulos received his M.D. from the Stanford University School of Medicine and his B.S. from Stanford University.

What is Peter A. Demopulos' net worth?: The estimated net worth of Peter A. Demopulos is at least $2.30 million as of November 15th, 2023. Dr. Demopulos owns 208,516 shares of Omeros stock worth more than $2,299,931 as of December 4th. This net worth estimate does not reflect any other investments that Dr. Demopulos may own. Learn More about Peter A. Demopulos' net worth.
How do I contact Peter A. Demopulos?: The corporate mailing address for Dr. Demopulos and other Omeros executives is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. Omeros can also be reached via phone at (206) 676-5000 and via email at [email protected]. Learn More on Peter A. Demopulos' contact information.
Has Peter A. Demopulos been buying or selling shares of Omeros?: Peter A. Demopulos has not been actively trading shares of Omeros during the past quarter. Most recently, on Wednesday, November 15th, Peter A. Md Demopulos bought 10,000 shares of Omeros stock. The stock was acquired at an average cost of $1.53 per share, with a total value of $15,300.00. Following the completion of the transaction, the director now directly owns 208,516 shares of the company's stock, valued at $319,029.48. Learn More on Peter A. Demopulos' trading history.
Who are Omeros' active insiders?: Omeros' insider roster includes Gregory Demopulos (CEO), Peter Demopulos (Director), and Michael Jacobsen (CAO). Learn More on Omeros' active insiders.

Peter A. Demopulos Insider Trading History at Omeros

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/15/2023	Buy	10,000	$1.53	$15,300.00	208,516
9/4/2015	Buy	3,962	$12.68	$50,238.16	185,182
6/24/2014	Buy	6,153	$16.20	$99,678.60

Peter A. Demopulos Buying and Selling Activity at Omeros

Omeros Company Overview

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Today's Range

Now: $11.03

$10.34

$11.03

50 Day Range

MA: $7.25

$4.10

$11.03

2 Week Range

Now: $11.03

$2.95

$13.60

Volume

1,265,693 shs

Average Volume

1,723,945 shs

Market Capitalization

$782.03 million

P/E Ratio

N/A

Dividend Yield